← Back to Search

Beta Blocker

Propranolol for Autism

Phase 2
Waitlist Available
Led By Barbie Zimmerman-Bier, M.D.
Research Sponsored by Rutgers, The State University of New Jersey
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up weekly through study completion, up to 7 months
Awards & highlights

Summary

This trial will help to determine if propranolol is a safe and effective treatment for severe challenging behaviors in ASD.

Who is the study for?
This trial is for New Jersey residents aged 12-30 with Autism Spectrum Disorder who exhibit severe aggression or self-injury and haven't improved enough on two psychotropic drugs, including an antipsychotic. Participants must have a confirmed autism diagnosis, be medically and cardiac cleared, and not have uncontrolled seizures or conditions that propranolol could worsen.
What is being tested?
The study tests high-dose propranolol's safety and effectiveness against challenging behaviors in autism compared to a placebo. Participants will switch between the drug and placebo during the trial. Cardiac safety is monitored through initial testing followed by remote check-ups to reduce office visits.
What are the potential side effects?
Propranolol can cause changes in blood pressure, heart function issues, may affect breathing in people with bronchial disorders like asthma, and isn't safe for those with certain heart diseases or diabetes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~weekly through study completion, up to 7 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and weekly through study completion, up to 7 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Aberrant Behavior Checklist (ABC-C)
Secondary study objectives
Change in Clinical Global Impression Scale (CGI)
Change in Modified Overt Aggression Scale (IBR-MOAS)
Change in Questions About Behavior Function (QABF)
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Group A: Propranolol firstExperimental Treatment1 Intervention
Participants randomly assigned to this group will receive Propranolol first. After the washout period, they will receive Placebo. Propranolol will be given in liquid or pill form.
Group II: Group B: Placebo firstPlacebo Group1 Intervention
Participants randomly assigned to this group will receive Placebo first. After the washout period, they will receive Propranolol. Placebo will look identical to the study drug Propranolol.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Propranolol
FDA approved

Find a Location

Who is running the clinical trial?

Rutgers, The State University of New JerseyLead Sponsor
440 Previous Clinical Trials
65,376 Total Patients Enrolled
9 Trials studying Autism Spectrum Disorder
171 Patients Enrolled for Autism Spectrum Disorder
New Jersey Governor's Council for Medical Research and Treatment of AutismUNKNOWN
1 Previous Clinical Trials
30 Total Patients Enrolled
New York State Institute for Basic ResearchOTHER_GOV
6 Previous Clinical Trials
958 Total Patients Enrolled
4 Trials studying Autism Spectrum Disorder
259 Patients Enrolled for Autism Spectrum Disorder

Media Library

Propranolol (Beta Blocker) Clinical Trial Eligibility Overview. Trial Name: NCT04047355 — Phase 2
Autism Spectrum Disorder Research Study Groups: Group B: Placebo first, Group A: Propranolol first
Autism Spectrum Disorder Clinical Trial 2023: Propranolol Highlights & Side Effects. Trial Name: NCT04047355 — Phase 2
Propranolol (Beta Blocker) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04047355 — Phase 2
~0 spots leftby Dec 2024